Newsletter 15

Indian MedTech|AI Innovation: Qure.ai

Qure.ai, headquartered in Mumbai, is revolutionizing radiology with AI-powered diagnostic tools. Their flagship product, qXR, uses deep learning to analyze chest X-rays, detecting abnormalities like tuberculosis and lung cancer with 95%+ accuracy. Their qER platform aids in early detection of brain abnormalities, including strokes, by analyzing CT scans in under 10 minutes, enabling faster clinical decisions.

The company’s recent advancements include qTrack, a tool for monitoring disease progression in chronic lung conditions, which has shown a 30% improvement in patient follow-up rates in pilot studies.

Deployed in over 2000 sites across 80 countries, Qure.ai enhances diagnostic speed and accessibility, particularly in underserved regions.

Interested in exploring their AI solutions? Yes!

Here is what to expect in today’s newsletter:

Read time: 5 minutes

The Big Question for Investors: Will early-stage healthtech investments yield higher returns than late-stage consolidations in India’s rapidly growing healthcare market?

Early-Stage Focus: Seed and Series A Surge

Late-Stage Consolidation: PE Dominance

Speaking of Investments,

How'd you justify this OUTLIER-FACT that Temasek-fueled-𝐌𝐚𝐧𝐢𝐩𝐚𝐥 paid ₹4.3Cr/Bed to buy out Pune's 1400-bed Sahyadri Hospitals?

This is the biggest anyone has ever paid to acquire any hospital in🇮🇳!!

Neodocs, offers smartphone-based at-home diagnostic kits for hemoglobin, urine ACR, sperm count, and ovulation, delivering instant, affordable results via a mobile app.

Modaro Health, connects patients to affordable, world-class medical treatments in India and abroad, managing travel and care with zero wait times.

Nexera Health, provides a comprehensive corporate wellness platform with teleconsultations, diagnostics, and mental health support, boosting employee engagement by 55%+.

NeuraSim Health, pioneers VR-based therapy for amblyopia with BeeVee™, improving vision through gamified modules.

Giga Health, offers India’s first hospitalization concierge, streamlining patient care with personalized support for paperwork and bedside assistance.

A small Cutaway…:)

…. Back to Updates

AarogyaAI, a Bangalore-based healthtech startup founded in 2019 by Dr. Praapti Jayaswal (CEO) and Avlokita Tiwari (CTO), leverages artificial intelligence (AI) and genomics to deliver precision diagnostics for antimicrobial resistance (AMR), with a primary focus on drug-resistant tuberculosis (DR-TB). Their AI-enabled Software-as-a-Service (SaaS) platform analyzes DNA sequences from patient samples using machine learning algorithms to generate comprehensive drug susceptibility reports within hours, a 100x improvement over traditional methods that take weeks.

The platform is pathogen- and sequencing hardware-agnostic, accessible across devices (desktops, mobiles, tablets), and built on global and local databases to detect both known and novel resistance mutations.

AarogyaAI has achieved significant milestones, including raising $700,000 in seed funding from investors

SigTuple, founded in 2015 by Tathagato Rai Dastidar, Rohit Kumar Pandey, and Apurv Anand in Bangalore, India, is a healthtech startup revolutionizing medical diagnostics through AI-powered digital microscopy solutions. Their flagship product, AI100, automates the analysis of peripheral blood smears, urine samples, and other microscopy data using artificial intelligence, robotics, microfluidics, and cloud computing.

The platform, which includes solutions like Shonit™ for blood smear analysis and Shrava™ for audiometry, enhances diagnostic accuracy, speed, and accessibility by digitizing samples and enabling remote review by pathologists.

SigTuple has raised $54.7M over nine funding rounds, with its latest $4M Series C extension in August 2024